A randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in ever Smokers with Extended Disease Small Cell Lung Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study evaluated whether an addition of simvastatin to chemotherapy improves survival in ever-smokers with extensive disease (ED)–small cell lung cancer (SCLC). Materials and Methods This is an open-label randomized phase II study conducted in National Cancer Center (Goyang, Korea). Chemonaive patients with ED-SCLC, smoking history (≥ 100 cigarettes lifetime), and Eastern Cooperative Oncology Group performance status of ≤ 2 were eligible. Patients were randomized to receive irinotecan plus cisplatin alone or with simvastatin (40 mg once daily orally) for a maximum of six cycles. Primary endpoint was the the 1-year survival rate. Results Between September 16, 2011, and September 9, 2021, 125 patients were randomly assigned to the simvastatin (n=62) or control (n=63) groups. The median smoking pack year was 40 years. There was no significant difference in the 1-year survival rate between the simvastatin and control groups (53.2% vs. 58.7%, p=0.535). The median progression-free survival and overall survival between the simvastatin arm vs. the control groups were 6.3 months vs. 6.4 months (p=0.686), and 14.4 months vs. 15.2 months, respectively (p=0.749). The incidence of grade 3-4 adverse events was 62.9% in the simvastatin group and 61.9% in the control group. In the exploratory analysis of lipid profiles, patients with hypertriglyceridemia had significantly higher 1-year survival rates than those with normal triglyceride levels (80.0% vs. 52.7%, p=0.046). Conclusion Addition of simvastatin to chemotherapy provided no survival benefit in ever-smokers with ED-SCLC. Hypertriglyceridemia may be associated with better prognosis in these patient population.
Abstract
Purpose This study evaluated whether an addition of simvastatin to chemotherapy improves survival in ever-smokers with extensive disease (ED)–small cell lung cancer (SCLC). Materials and Methods This is an open-label randomized phase II study conducted in National Cancer Center (Goyang, Korea). Chemonaive patients with ED-SCLC, smoking history (≥ 100 cigarettes lifetime), and Eastern Cooperative Oncology Group performance status of ≤ 2 were eligible. Patients were randomized to receive irinotecan plus cisplatin alone or with simvastatin (40 mg once daily orally) for a maximum of six cycles. Primary endpoint was the the 1-year survival rate. Results Between September 16, 2011, and September 9, 2021, 125 patients were randomly assigned to the simvastatin (n=62) or control (n=63) groups. The median smoking pack year was 40 years. There was no significant difference in the 1-year survival rate between the simvastatin and control groups (53.2% vs. 58.7%, p=0.535). The median progression-free survival and overall survival between the simvastatin arm vs. the control groups were 6.3 months vs. 6.4 months (p=0.686), and 14.4 months vs. 15.2 months, respectively (p=0.749). The incidence of grade 3-4 adverse events was 62.9% in the simvastatin group and 61.9% in the control group. In the exploratory analysis of lipid profiles, patients with hypertriglyceridemia had significantly higher 1-year survival rates than those with normal triglyceride levels (80.0% vs. 52.7%, p=0.046). Conclusion Addition of simvastatin to chemotherapy provided no survival benefit in ever-smokers with ED-SCLC. Hypertriglyceridemia may be associated with better prognosis in these patient population.
참고문헌 (31)
- Jemal A, "Cancer statistics, 2010", CA Cancer J Clin, 60, pp.277~300 (2010)
- Rudin CM, "Treatment of small-cell lung cancer : American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline", J Clin Oncol, 33, pp.4106~4111 (2015)
- Demierre MF, "Statins and cancer prevention", Nat Rev Cancer, 5, pp.930~942 (2005)
- Longo J, "Statins as anticancer agents in the era of precision medicine", Clin Cancer Res, 26, pp.5791~5800 (2020)
- Chan KK, "The statins as anticancer agents", Clin Cancer Res, 9, pp.10~19 (2003)
- Roudier E, "Statins induce mammalian target of rapamycin(mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs", Mol Cancer Ther, 5, pp.2706~2715 (2006)
- Park IH, "Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity", Invest New Drugs, 29, pp.883~890 (2011)
- Khurana V, "Statins reduce the risk of lung cancer in humans : a large case-control study of US veterans", Chest, 131, pp.1282~1288 (2007)
- Farwell WR, "The association between statins and cancer incidence in a veterans population", J Natl Cancer Inst, 100, pp.134~139 (2008)
- Khanzada UK, "Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling", Oncogene, 25, pp.877~887 (2006)
- Han JY, "A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer", Cancer, 117, pp.2178~2185 (2011)
- Armato SG 3rd, "Revised modified Response Evaluation Criteria in Solid Tumors for assessment of res-ponse in malignant pleural mesothelioma(version 1. 1)", J Thorac Oncol, 13, pp.1012~1021 (2018)
- Lee Jae Guk, "Recent Trends of Lung Cancer in Korea", Tuberculosis and Respiratory Diseases, 84(2), pp.89~95 (2021), 대한결핵및호흡기학회[DOI]
- Seckl MJ, "Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer(LUNGSTAR)", J Clin Oncol, 35, pp.1506~1514 (2017)
- Jouve JL, "Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma", J Hepatol, 71, pp.516~522 (2019)
- Kawata S, "Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma : a randomized controlled trial", Br J Cancer, 84, pp.886~891 (2001)
- Hus M, "Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma", Ann Hematol, 90, pp.1161~1166 (2011)
- Tsurutani J, "Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells", Carcinogenesis, 26, pp.1182~1195 (2005)
- Garwood ER, "Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer", Breast Cancer Res Treat, 119, pp.137~144 (2010)
- Yu R, "Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins", Cancer Res, 78, pp.1347~1357 (2018)
- Liu SV, "Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide(IMpower133)", J Clin Oncol, 39, pp.619~630 (2021)
- Sun H, "Triglyceride-to-high density lipoprotein cholesterol ratio predicts clinical outcomes in patients with gastric cancer", J Cancer, 10, pp.6829~6836 (2019)
- Li X, "The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer", Breast, 32, pp.1~6 (2017)
- Shepshelovich D, "Body mass index(BMI), BMI change, and overall survival in patients with SCLC and NSCLC : a pooled analysis of the International Lung Cancer Consortium", J Thorac Oncol, 14, pp.1594~1607 (2019)
- McQuade JL, "Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysis", Lancet Oncol, 19, pp.310~322 (2018)
- Wang Z, "Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade", Nat Med, 25, pp.141~151 (2019)
- Go SI, "Clinical significance of the cachexia index in patients with small cell lung cancer", BMC Cancer, 21, pp.563~ (2021)
- Kim EY, "Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer", Eur J Cancer Care(Engl), 27, pp.e12695~ (2018)
- Das SK, "The role of triglyceride lipases in cancer associated cachexia", Trends Mol Med, 19, pp.292~301 (2013)
- Jones A, "TSC22D4 is a molecular output of hepatic wasting metabolism", EMBO Mol Med, 5, pp.294~308 (2013)
- Briddon S, "Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model", Cancer Lett, 57, pp.49~53 (1991)